Neonatal MSG treatment is a model of obesity in rodents which causes alterations in hypothalamic arcuate nucleus (ARC) and impairs leptin and insulin signaling in this region [37-39] resulting in hyperleptinemia and hyperinsulinemia. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.